206 results on '"Kamath, Amrita V."'
Search Results
2. A Bispecific Modeling Framework Enables the Prediction of Efficacy, Toxicity, and Optimal Molecular Design of Bispecific Antibodies Targeting MerTK
3. Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases
4. Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma
5. A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule
6. Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development
7. Balancing the Affinity and Pharmacokinetics of Antibodies by Modulating the Size of Charge Patches on Complementarity-Determining Regions
8. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic
9. Supplementary Information from Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers
10. Data from Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers
11. Supplementary Data from Calicheamicin Antibody–Drug Conjugates with Improved Properties
12. Supplementary Data from Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics
13. Supplementary Data from Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration
14. Supplementary information from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
15. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies
16. Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
17. Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies
18. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
19. Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
20. Pharmacokinetics of Antibody-Drug Conjugates
21. Challenges and advances in the assessment of the disposition of antibody-drug conjugates
22. Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics
23. Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration
24. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
25. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
26. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
27. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
28. Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics
29. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
30. Calicheamicin Antibody–Drug Conjugates with Improved Properties
31. Modulation of tight junctions does not predict oral absorption of hydrophilic compounds: Use of caco-2 and calu-3 cells
32. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog
33. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats
34. Choline uptake in human intestinal Caco-2 cells is carrier-mediated
35. Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti–Staphylococcus aureus THIOMAB Antibody-Antibiotic Conjugate in Rats
36. Complex formation of anti‐VEGF‐C with VEGF‐C released during blood coagulation resulted in an artifact in its serum pharmacokinetics
37. Front Cover: Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity (ChemMedChem 1/2020)
38. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
39. Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules
40. Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging
41. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against Staphylococcus aureus
42. Prediction of Human Pharmacokinetics of Antibody–Drug Conjugates From Nonclinical Data
43. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers
44. Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo
45. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties
46. Complex formation of anti-VEGF-C with VEGF-C released during blood coagulation resulted in an artifact in its serum pharmacokinetics.
47. Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity.
48. Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia
49. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model
50. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.